IONIS PHARMACEUTICALS, INC.

Lobbying client. Federal LDA filings.

Connected on the graph

Inbound (7)

date	from	type	amount	source
—	Jordan Chapman	lobbied_for	—	lda_lobbyist_client
—	Sophie Khanahmadi	lobbied_for	—	lda_lobbyist_client
—	Sonia Goh	lobbied_for	—	lda_lobbyist_client
—	Maximilian Walter	lobbied_for	—	lda_lobbyist_client
—	Alanna Temme	lobbied_for	—	lda_lobbyist_client
2026-01-01	LMH STRATEGIC SOLUTIONS	lobbies_for	$30,000	lda_filing
2026-01-01	IONIS PHARMACEUTICALS, INC.	lobbies_for	$150,000	lda_filing

Outbound (9)

date	type	to	amount	role	source
2026-01-01	lobbies_on_bill	HR 1262 — Mikaela Naylon Give Kids a Chance Act	—	H.R.1262	lobbying_bill_mention
2026-01-01	lobbies_on_bill	HR 1672 — Maintaining Investments in New Innovation Act	—	H.R.1672	lobbying_bill_mention
2026-01-01	lobbies_on_bill	HR 946 — ORPHAN Cures Act	—	H.R.946	lobbying_bill_mention
2026-01-01	lobbies_on_bill	S 1862 — ORPHAN Cures Act	—	S.1862	lobbying_bill_mention
2026-01-01	lobbies_on_bill	S 932 — Give Kids a Chance Act of 2025	—	S.932	lobbying_bill_mention
2026-01-01	lobbies_on_bill	HR 1262 — Mikaela Naylon Give Kids a Chance Act	—	H.R.1262	lobbying_bill_mention
2026-01-01	lobbies_on_bill	HR 1414 — Cameron’s Law	—	H.R.1414	lobbying_bill_mention
2026-01-01	lobbies_on_bill	HR 1672 — Maintaining Investments in New Innovation Act	—	H.R.1672	lobbying_bill_mention
2026-01-01	lobbies_on_bill	S 932 — Give Kids a Chance Act of 2025	—	S.932	lobbying_bill_mention

Source id: 61063
General description: Biotechnology company.
State: CA
Country: US
Principal place of business: US
Effective date: 2024-07-01
Total spend (across 1 ingested filings): $0

Filings

Posted	Type	Year	Lobbying firm	Income
2026-04-09	`Q1`	2026	IONIS PHARMACEUTICALS, INC.	—

pac.dog is a free, independent, non-partisan research tool. Every candidate, committee, bill, vote, member, and nonprofit on this site is mirrored from primary U.S. government sources (FEC, congress.gov, govinfo.gov, IRS) and each state's Secretary of State / election commission — no third-party data vendors, no paywall, no editorial intermediation. Citations to the originating source are on every detail page.